India Publishes Draft Import Guidance for IVD Medical Devices (2026)

In early 2026, India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), issued a new draft guidance document aimed at simplifying and clarifying the regulatory requirements for importing In-Vitro Diagnostic (IVD) medical devices into the Indian market.

The draft guidance, officially titled “Guidance for Import of In-Vitro Diagnostic Medical Device” (No. CDSCO/IVD/GD/DRAFT/IMP/01/2026), was released for public feedback in January 2026 and invites comments from stakeholders within a specified comment period.

Context and Purpose

Under the Medical Devices Rules, 2017, medical devices, including IVDs, must meet regulatory requirements for registration, import, and marketing. However, historically, companies, particularly foreign manufacturers and their Indian authorised agents, have faced challenges navigating the import licence process due to ambiguity and inconsistent expectations around documentation and submission pathways.

The new draft guidance aims to address those gaps by providing detailed procedural direction that aligns the regulatory framework with practical application pathways, including submission expectations and checklist items for different licence types.

Key Features of the Draft Guidance

According to the draft and industry summaries:

• The guidance clarifies how import licence applications should be structured, including information required for Forms MD-14 (registration) and MD-16 (test licence) submissions.

• It sets out detailed documentation expectations such as Device Master File (DMF), Plant Master File (PMF), quality management system (ISO 13485) certification, Free Sale Certificates, performance evaluation data, stability reports and post-market surveillance strategies.

• Performance evaluation reports and stability data are highlighted as core evidence components, particularly for critical IVDs, to ensure accurate regulatory assessment.

• The draft also describes submissions through consolidated portals such as the CDSCO online system and the National Single Window System (NSWS), reflecting broader digitalisation of regulatory processes.

• Stakeholders are encouraged to provide feedback within 15 days of publication, indicating an open consultative approach to formulating the final guidance.

These elements are designed to improve transparency and reduce uncertainty around import regulatory expectations.

Why This Matters to Industry Stakeholders

This draft guidance has practical and strategic implications for organisations involved in importing IVDs into India:

1. Regulatory Clarity and Predictability

With clear application structures and well-defined documentation requirements, importers will be better equipped to prepare complete and compliant submissions.

2. Enhanced Submission Quality

Detailed checklists and guidance help standardise dossier preparation, reducing the risk of queries and rejections that can delay regulatory decisions.

3. Alignment with Digital Regulatory Platforms

By specifying pathways through the CDSCO online portal and NSWS, the guidance supports the Indian government’s broader push toward digitalisation, efficiency, and transparency.

4. Opportunity for Stakeholder Engagement

The comment period allows manufacturers, authorised representatives and industry associations to contribute to shaping the final guidance, helping ensure that regulatory expectations align with industry realities.

Preparing for Implementation

Although still in draft form, this guidance signals CDSCO’s continued focus on improving regulatory pathways for medical devices in India. Stakeholders planning to import IVDs, including diagnostic kits and test systems, should:

• Review the draft guidance to identify changes from existing practice.

• Map current documentation and submission workflows against new expectations;

• Provide formal feedback during the consultation period where appropriate.

• Update internal regulatory SOPs and submission strategies in anticipation of the final guidance.

Looking Ahead

The draft guidance represents another step in India’s evolving medical device regulatory landscape, where clarity, process efficiency, and alignment with international best practices are increasingly prioritised. Finalisation of this guidance is expected to bring greater confidence, predictability, and transparency to the IVD import approval process, benefiting both regulators and industry alike.

Source: Draft Guidance for Import of In-Vitro Diagnostic Medical Device (No. CDSCO/IVD/GD/DRAFT/IMP/01/2026) Central Drugs Standard Control Organization, Government of India (draft released for stakeholder comments, Jan 2026).